phenylacetylglutamine

Phenylacetylglutamine is a naturally occurring human metabolite formed by the conjugation of phenylacetate and glutamine. It is produced in the liver as an alternative pathway for nitrogen waste removal, especially under uremic conditions or in patients with urea cycle disorders[1][4]. Phenylacetylglutamine is also generated as a primary metabolite from the degradation of pharmaceutical agents such as sodium phenylbutyrate and sodium phenylacetate[1]. In humans, it serves to excrete excess nitrogen via urine when the urea cycle is impaired. Additionally, phenylacetylglutamine has been identified as a gut microbiota-derived metabolite (PAGln) implicated in cardiovascular and cerebrovascular diseases; elevated levels are associated with increased risk of heart failure and coronary artery disease[5][6]. Chemically identical to Antineoplaston AS2-5, it has been investigated experimentally for cancer therapy by S.R. Burzynski under the name "antineoplastons," though this use remains unproven and controversial[8].

Other names

Antineoplaston AS2-5PAGlnN-phenylacetyl-L-glutamine